Health Care • Medical/Dental Instruments
$0.65 ▲ +0.02
(+2.94%)
MKT CAP: $1.4M • VOL: 220.7K
52W L $1 52W H $31
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
VJET // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $819.0K | $420.0K | $442.0K |
| YoY Revenue Growth % | +95.0% | -5.0% | — |
| Gross Profit | $756.0K | $378.0K | — |
| Gross Margin % | 92.3% | 90.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.1M | -$11.2M | -$78.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.2M | -$16.6M | -$70.6M |
| EBITDA (Normalized) | -$21.1M | -$11.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.3M | -$9.3M | -$20.6M |
| Capital Expenditures (CapEx) | $17.0K | $67.0K | — |
| Free Cash Flow (FCF) | -$8.3M | -$9.3M | -$20.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $88.0K | $2.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.1M | $11.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VJET.